AbbVie Inc. (ABBV) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
AbbVie Inc. stock price
AbbVie Inc. latest news:
BRIEF-AbbVie announces positive topline results from phase 3 trial evaluating Venclexta/Venclyxto tablets in combination with Rituxan
* AbbVie announces positive topline results from phase 3
trial evaluating Venclexta™/Venclyxto™ (Venetoclax) tablets in
combination with Rituxan® (Rituximab) for the treatment of
patients with relapsed/refractory chronic lymphocytic Leukemia
AbbVie says deaths in arthritis trial not linked to drug
AbbVie Inc(ABBV) said on Monday two patients died in a late-stage trial of its rheumatoid arthritis drug but that the deaths were not linked to the drug, which met the study's main goals.
UPDATE 2-AbbVie says deaths in arthritis trial not linked to drug
Sept 11 (Reuters) - AbbVie Inc said on Monday two
patients died in a late-stage trial of its rheumatoid arthritis
drug but that the deaths were not linked to the drug, which met
the study's main goals.
BRIEF-Inventiva and AbbVie extend agreement
INVENTIVA SA: * INVENTIVA AND ABBVIE EXTEND AGREEMENT TO DISCOVER NEW POTENT ORALLY-AVAILABLE SMALL MOLECULE RORΓ INVERSE AGONIST DRUG CANDIDATES.
REFILE-BRIEF-AbbVie to delist from Euronext Paris
* This request has been approved by the Board of Directors
of Euronext Paris SA
AbbVie's drug for all types of hepatitis C wins EU approval
July 28 (Reuters) - AbbVie Inc said on Friday it
had received European approval to market its drug for treatment
of all six major forms of hepatitis C.
AbbVie Slips Despite Q2 Earnings Beat
AbbVie shares surge 2% on Q2 profit, revenue beats
AbbVie Inc. shares surged 2% in premarket trade Friday after the company reported second-quarter profit and revenue beats. Earnings for the latest quarter rose to $1.92 billion, or $1.19 per share, from $1.61 billion, or 98 cents per share in the year-earlier period. Adjusted earnings-per-share were $1.42, compared with the FactSet consensus of $1.40. Revenue rose to $6.94 billion from $6.45 billion, compared with the FactSet consensus of $6.93 billion. Revenue for anti-inflammatory Humira came in at $4.72 billion, above the FactSet consensus of $4.64 billion. Revenue for cancer drug Imbruvica came to $626 million, above the FactSet consensus of $608 million. Revenue for the Hepatitis C therapy Viekira came in at $225 million, below the FactSet consensus of $251 million. Revenue for the therapy Lupron, which is used to delay the onset of puberty, came in above the FactSet consensus, and revenue for digestive drug Creon came in just below the FactSet consensus. The company also confirmed its 2017 EPS and adjusted EPS guidance. AbbVie shares have surged 8.8% over the last three months, compared with a 3.8% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Abercrombie & Fitch CompanyANF
Aberdeen Greater China FundGCH
Aberdeen Japan Equity FundJEQ
Aberdeen Singapore FundSGF
ABM Industries IncorporatedABM
Acadia Realty TrustAKR
Acco Brands CorporationACCO
Accuride Corporation NewACW